|
Ventricular Septal Defects
|
0.410 |
Biomarker
|
group |
CTD_human |
Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome.
|
30067223 |
2018 |
|
Ventricular Septal Defects
|
0.410 |
Biomarker
|
group |
BEFREE |
Our finding is the first to suggest that SALL4 may be a potential candidate gene of ventricular septal defect (VSD).
|
19619907 |
2010 |
|
Ventricular Septal Defects
|
0.410 |
Biomarker
|
group |
HPO |
|
|
|
|
Limb Deformities, Congenital
|
0.300 |
Biomarker
|
group |
CTD_human |
Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome.
|
30067223 |
2018 |
|
Craniofacial Abnormalities
|
0.300 |
Biomarker
|
group |
CTD_human |
A SALL4 zinc finger missense mutation predicted to result in increased DNA binding affinity is associated with cranial midline defects and mild features of Okihiro syndrome.
|
16402211 |
2006 |
|
Atrial Septal Defects
|
0.110 |
Biomarker
|
group |
HPO |
|
|
|
|
Atrial Septal Defects
|
0.110 |
Biomarker
|
group |
BEFREE |
The presence of single atrioventricular canal instead of the atrial septal defect typical for Holt-Oram syndrome pointed us to rather suspect the SALL4 related diseases.
|
28807863 |
2017 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
No obvious correlations were detected between clinicopathological factors and SALL4 mRNA expression; however, SALL4 mRNA was expressed at a high level even in the early clinical stages of the cancer.
|
21274508 |
2011 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This result agreed with the negative correlation between SALL4 expression and overall survival period obtaining in GBM patients from the cancer genome atlas database.
|
25359397 |
2015 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
While the expression of SALL4 is normally restricted to ESCs and somatic stem cells, we found that it is aberrantly expressed in ALK-positive anaplastic large cell lymphoma (ALK+ ALCL), a type of lymphoid malignancy carrying a mature T-cell immunophenotype. shRNA knockdown of SALL4 in ALK+ ALCL cell lines resulted in apoptosis and cell-cycle arrest, and significantly decreased colony formation on soft agar.
|
22743134 |
2012 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
SALL4 expression measured before adjuvant chemotherapy was significantly higher in the patients showing recurrence of cancer than in the disease-free patients.
|
25646965 |
2015 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
SALL4 is a vital factor in the development and prognosis of various cancers, but its role in radioresistance remains elusive.
|
30907073 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Although the detailed mechanism remains unclear, dysregulation of SALL4 has been detected in various malignancies.
|
28943937 |
2017 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
SALL4, the missing link between stem cells, development and cancer.
|
26892498 |
2016 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our study reveal novel function of Ku80 in stemness maintaining of cancer stem cells via its interaction with SALL4 and highlight the double-sidedness of Ku80 as an anti-cancer target.
|
31816404 |
2020 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Impaired DDR in SALL4-deficient human cancer cells can be rescued by the restored expression of Glut1, indicating the importance of HP1α-Glut1 axis in SALL4-mediated DDR.
|
28759035 |
2017 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In this study, 175 well-characterized primary diffuse pleural mesotheliomas, including the epithelioid (n = 148), biphasic (n = 15), and sarcomatoid (n = 12) histotypes, were evaluated immunohistochemically for cancer stem cell markers (ALCAM, ALDH1, and SALL4) and PD-L1 expression.
|
28811252 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Sall4 is a novel oncogene found upregulated in several malignancies including colon cancer.
|
26238082 |
2015 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, we found that SALL4 was significantly upregulated in HCC tissues compared to their matched adjacent normal tissues, and its increased expression was significantly associated with the advanced malignancy of HCC.
|
28026002 |
2016 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Increasing evidence suggests that SALL4 plays oncogenic roles in cancer development and progression.
|
30349378 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This led to our investigation of the implication of SALL4 in drug resistance and its role in side population (SP) cancer stem cells.
|
21526180 |
2011 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results revealed that SALL4 might serve as a functional marker for ESCC cancer stem cell, a crucial marker for prognosis and an attractive candidate for target therapy of ESCC.
|
27329034 |
2016 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The prognostic value of SALL4 expression in cancer patients was evaluated by pooled hazard ratios (HRs) and 95% confidence intervals (CIs).
|
28582841 |
2017 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Reports of SALL4 serological levels linked to HCC patients are meager and unclear in the prognosis of this malignancy.
|
24860834 |
2014 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
SALL4 expression is inherent in the upregulations of endothelial mesenchymal transition (EMT) genes and therefore promoting cancer metastasis.
|
29958885 |
2018 |